Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.

Wagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, Farlow MR, Clifford DB, Supnet-Bell C, Santacruz AM, Aschenbrenner AJ, Hassenstab JJ, Benzinger TLS, Gordon BA, Coalier KA, Cruchaga C, Ibanez L, Perrin RJ, Xiong C, Li Y, Morris JC, Lah JJ, Berman SB, Roberson ED, van Dyck CH, Galasko D, Gauthier S, Hsiung GR, Brooks WS, Pariente J, Mummery CJ, Day GS, Ringman JM, Mendez PC, St George-Hyslop P, Fox NC, Suzuki K, Okhravi HR, Chhatwal J, Levin J, Jucker M, Sims JR, Holdridge KC, Proctor NK, Yaari R, Andersen SW, Mancini M, Llibre-Guerra J, Bateman RJ, McDade E, Dominantly Inherited Alzheimer Network–Trials Unit

Open source

DOI: 10.1001/jamaneurol.2024.0991
Published: 2024 Jun 1
Container: JAMA neurology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaneurol.2024.0991,
  title = {Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.},
  author = {Wagemann O and Liu H and Wang G and Shi X and Bittner T and Scelsi MA and Farlow MR and Clifford DB and Supnet-Bell C and Santacruz AM and Aschenbrenner AJ and Hassenstab JJ and Benzinger TLS and Gordon BA and Coalier KA and Cruchaga C and Ibanez L and Perrin RJ and Xiong C and Li Y and Morris JC and Lah JJ and Berman SB and Roberson ED and van Dyck CH and Galasko D and Gauthier S and Hsiung GR and Brooks WS and Pariente J and Mummery CJ and Day GS and Ringman JM and Mendez PC and St George-Hyslop P and Fox NC and Suzuki K and Okhravi HR and Chhatwal J and Levin J and Jucker M and Sims JR and Holdridge KC and Proctor NK and Yaari R and Andersen SW and Mancini M and Llibre-Guerra J and Bateman RJ and McDade E and Dominantly Inherited Alzheimer Network–Trials Unit},
  year = {2024},
  journal = {JAMA neurology},
  doi = {10.1001/jamaneurol.2024.0991},
  url = {https://doi.org/10.1001/jamaneurol.2024.0991}
}

RIS

TY  - JOUR
TI  - Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
AU  - Wagemann O
AU  - Liu H
AU  - Wang G
AU  - Shi X
AU  - Bittner T
AU  - Scelsi MA
AU  - Farlow MR
AU  - Clifford DB
AU  - Supnet-Bell C
AU  - Santacruz AM
AU  - Aschenbrenner AJ
AU  - Hassenstab JJ
AU  - Benzinger TLS
AU  - Gordon BA
AU  - Coalier KA
AU  - Cruchaga C
AU  - Ibanez L
AU  - Perrin RJ
AU  - Xiong C
AU  - Li Y
AU  - Morris JC
AU  - Lah JJ
AU  - Berman SB
AU  - Roberson ED
AU  - van Dyck CH
AU  - Galasko D
AU  - Gauthier S
AU  - Hsiung GR
AU  - Brooks WS
AU  - Pariente J
AU  - Mummery CJ
AU  - Day GS
AU  - Ringman JM
AU  - Mendez PC
AU  - St George-Hyslop P
AU  - Fox NC
AU  - Suzuki K
AU  - Okhravi HR
AU  - Chhatwal J
AU  - Levin J
AU  - Jucker M
AU  - Sims JR
AU  - Holdridge KC
AU  - Proctor NK
AU  - Yaari R
AU  - Andersen SW
AU  - Mancini M
AU  - Llibre-Guerra J
AU  - Bateman RJ
AU  - McDade E
AU  - Dominantly Inherited Alzheimer Network–Trials Unit
PY  - 2024
JO  - JAMA neurology
DO  - 10.1001/jamaneurol.2024.0991
UR  - https://doi.org/10.1001/jamaneurol.2024.0991
ER  -

APA

O, W., H, L., G, W., X, S., T, B., MA, S., MR, F., DB, C., C, S., AM, S., AJ, A., JJ, H., TLS, B., BA, G., KA, C., C, C., L, I., RJ, P., C, X., Y, L., JC, M., JJ, L., SB, B., ED, R., CH, V. D., D, G., S, G., GR, H., WS, B., J, P., CJ, M., GS, D., JM, R., PC, M., P, S. G., NC, F., K, S., HR, O., J, C., J, L., M, J., JR, S., KC, H., NK, P., R, Y., SW, A., M, M., J, L., RJ, B., E, M., & Unit, D. I. A. N. (2024). Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.. JAMA neurology. https://doi.org/10.1001/jamaneurol.2024.0991

Source records

pubmed · retrieved 2026-09-26T12:19:17.117Z
europe-pmc · retrieved 2026-09-26T12:19:17.121Z
hal · retrieved 2026-09-26T12:19:17.135Z